Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.41 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 3/20 | 0.32 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.32 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.32 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.32 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 2/20 | 0.30 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11856251 | 0.81 | LMNA (0.40) | LMNAPTGS1TRPA1CACNA1C | |
| SCHEMBL10830816 | 0.81 | S1PR1 (0.46) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL11863067 | 0.81 | LMNA (0.35) | LMNAPTGS1TRPA1CACNA1C | |
| SCHEMBL27755266 | 0.81 | CHRNA1 (0.38) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL11635848 | 0.79 | CYP3A4 (0.45) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL8299293 | 0.79 | AKR1C3 (0.45) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL10539163 | 0.79 | UGT2B7 (0.41) | LMNAPTGS1TRPA1CACNA1CTSHR | |
| SCHEMBL2336888 | 0.79 | LMNA (0.46) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL30475871 | 0.79 | LMNA (0.46) | LMNAPTGS1TRPA1CACNA1CALDH1A1 | |
| SCHEMBL29352459 | 0.79 | LMNA (0.46) | LMNAPTGS1TRPA1CACNA1CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-3962357-A | FROM SUBSTITUTED ETHYLTOLUENE, CONTINUOUS, SINGLE STEP | ROHM AND HAAS COMPANY (US) | 1976-06-08 | — | — | US | claimed |
| US-20210111355-A1 | Tetradentate Platinum And Palladium Complex Emitters Containing Phenyl-Pyrazole And Its Analogues | UNIV ARIZONA STATE (US) | 2021-04-15 | — | — | US | disclosed |
| US-8729110-B1 | 2-thio-1,3,4-oxadiazoles derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2014-05-20 | — | — | US | disclosed |
| US-7488748-B2 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2009-02-10 | — | — | US | disclosed |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | RANBAXY LABORATORIES LIMITED (IN) | 2006-11-02 | — | — | US | disclosed |
| EP-1590325-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES, LTD. (IN) | 2005-11-02 | — | — | EP | disclosed |
| WO-2004067510-A1 | 3,6-DISUBSTITUTED AZABICYCLO HEXANE DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS | RANBAXY LABORATORIES LIMITED (IN) | 2004-08-12 | — | — | WO | disclosed |
| EP-0950048-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI-SYNTHELABO (FR) | 1999-10-20 | — | — | EP | disclosed |
| WO-1998025903-A1 | 1-PHENYLALKYL-1,2,3,6-TETRAHYDROPYRIDINES FOR TREATING ALZHEIMER'S DISEASE | SANOFI (FR) | 1998-06-18 | — | — | WO | disclosed |
| US-3962357-A | FROM SUBSTITUTED ETHYLTOLUENE, CONTINUOUS, SINGLE STEP | ROHM AND HAAS COMPANY (US) | 1976-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210111355-A1 | Tetradentate Platinum And Palladium Complex Emitters Containing Phenyl-Pyrazole And Its Analogues | PDCD1, PDCD11, TYMP | LMNA 4731/4885PTGS1 3986/4885TRPA1 1685/4885 |
| US-20060247225-A1 | 3,6-Disubstituted azabicyclo hexane derivatives as muscarinic receptor antagonists | CHRM3, CHRM5, CHRM2 | LMNA 4583/4885PTGS1 1145/4885TRPA1 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.